Ebrima Gibbs

Title: Ebrima Gibbs: Innovator in Antibody Research

Introduction

Ebrima Gibbs is a notable inventor based in Port Moody, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies targeting amyloid-beta (A-beta) oligomers. With a total of 2 patents, his work is paving the way for advancements in therapeutic approaches to neurodegenerative diseases.

Latest Patents

Gibbs' latest patents include innovative methods and compositions related to humanized antibodies that bind to A-beta oligomers. The first patent focuses on antibodies that specifically target A-beta oligomers, detailing methods for their production and application. This patent also includes chimeric or humanized antibodies, featuring specific complementarity-determining regions (CDRs) as outlined in the provided tables. The second patent addresses methods for reducing toxicity induced by A-beta oligomers using these specific antibodies, further emphasizing their potential therapeutic uses.

Career Highlights

Throughout his career, Ebrima Gibbs has worked with esteemed institutions such as the University of British Columbia and Promis Neurosciences Inc. His research has been instrumental in advancing our understanding of amyloid-beta's role in neurodegenerative diseases, contributing to the development of potential treatments.

Collaborations

Gibbs has collaborated with notable researchers in the field, including Neil R. Cashman and Steven S. Plotkin. These collaborations have enriched his research and expanded the impact of his work in the scientific community.

Conclusion

Ebrima Gibbs stands out as an innovative inventor in the realm of antibody research, with a focus on addressing the challenges posed by amyloid-beta oligomers. His contributions are vital for the future of therapeutic interventions in neurodegenerative diseases.